Advisor Group Inc. Buys 389 Shares of Chemed Corp. (CHE)
Advisor Group Inc. increased its stake in shares of Chemed Corp. (NYSE:CHE) by 9.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 4,401 shares of the company’s stock after acquiring an additional 389 shares during the period. Advisor Group Inc.’s holdings in Chemed Corp. were worth $889,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Acrospire Investment Management LLC acquired a new position in Chemed Corp. during the 2nd quarter worth approximately $120,000. Pacad Investment Ltd. lifted its position in Chemed Corp. by 250.0% during the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after acquiring an additional 500 shares in the last quarter. IFP Advisors Inc lifted its position in Chemed Corp. by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after acquiring an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Chemed Corp. by 12.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after acquiring an additional 83 shares in the last quarter. Finally, MCF Advisors LLC acquired a new position in Chemed Corp. during the 3rd quarter worth approximately $152,000. 96.50% of the stock is currently owned by hedge funds and other institutional investors.
In other news, VP Michael D. Witzeman sold 1,579 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $235.00, for a total value of $371,065.00. Following the completion of the sale, the vice president now owns 4,334 shares in the company, valued at $1,018,490. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $197.46, for a total value of $197,460.00. Following the completion of the sale, the insider now owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The disclosure for this sale can be found here. Insiders have sold a total of 33,229 shares of company stock valued at $7,556,478 in the last quarter. 4.90% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: “Advisor Group Inc. Buys 389 Shares of Chemed Corp. (CHE)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/11/22/advisor-group-inc-buys-389-shares-of-chemed-corp-che.html.
Chemed Corp. (CHE) opened at $238.14 on Wednesday. The company has a market capitalization of $3,697.73, a price-to-earnings ratio of 28.52, a P/E/G ratio of 4.90 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. Chemed Corp. has a 52 week low of $145.35 and a 52 week high of $238.40.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings data on Thursday, October 26th. The company reported $2.15 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.15. The firm had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The firm’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the business earned $1.73 EPS. analysts anticipate that Chemed Corp. will post 4.73 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Investors of record on Monday, November 13th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, November 10th. This represents a $1.12 dividend on an annualized basis and a yield of 0.47%. Chemed Corp.’s payout ratio is currently 24.89%.
Several equities research analysts have issued reports on the company. Oppenheimer Holdings, Inc. lifted their price objective on Chemed Corp. from $220.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. National Bank Financial upgraded Chemed Corp. from a “sector perform market weight” rating to an “outperform market weight” rating in a report on Sunday, August 13th. Zacks Investment Research downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, September 13th. BidaskClub downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Royal Bank Of Canada reiterated a “hold” rating and issued a $209.00 price target on shares of Chemed Corp. in a report on Monday, July 31st. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Chemed Corp. currently has an average rating of “Hold” and a consensus price target of $236.00.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Stock Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related stocks with our FREE daily email newsletter.